Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Shutao Pan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8596-9387; OpenAlex author ID A5074071387. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2018: 4 papers · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 17

  1. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Co-author DOI 10.1038/s41418-026-01665-1↗
  2. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. First author DOI 10.1001/jamasurg.2023.5210↗
  3. A comparative study of the "superior mesenteric artery first" approach versus the conventional approach in short-term and long-term outcomes in patients with p… Co-author DOI 10.1007/s00464-023-10470-7↗
  4. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-022-01040-w↗
  5. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
  6. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  7. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analys… Co-author DOI 10.1016/j.pan.2021.12.005↗
  8. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. Co-author DOI 10.1136/bmjopen-2021-057128↗
  9. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. First author DOI 10.1186/s13046-022-02491-2↗
  10. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. First author DOI 10.3389/fonc.2021.765216↗
  11. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  12. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗
  13. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  14. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Co-author DOI 10.1016/j.taap.2018.08.003↗
  15. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Co-author DOI 10.1038/s41598-018-22493-5↗
  16. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Co-author DOI 10.18632/oncotarget.22976↗
  17. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Wang · 15 shared papers, 2018–2026 · strength 1.96
  2. Renyi Qin · 14 shared papers, 2018–2026 · strength 1.78
  3. Taoyuan Yin · 8 shared papers, 2019–2026 · strength 1.23
  4. Chunle Zhao · 8 shared papers, 2018–2026 · strength 1.01
  5. Zhenxiong Zhang · 6 shared papers, 2022–2026 · strength 1.01
  6. Xingjun Guo · 9 shared papers, 2018–2023 · strength 0.90
  7. Ruizhi He · 9 shared papers, 2018–2022 · strength 0.84
  8. Xiuhui Shi · 8 shared papers, 2018–2022 · strength 0.71
  9. Jun Gong · 4 shared papers, 2022–2026 · strength 0.71
  10. Min Zhou · 3 shared papers, 2023–2026 · strength 0.58
  11. Yongkang Shi · 3 shared papers, 2022–2026 · strength 0.55
  12. Min Zhou · 5 shared papers, 2018–2022 · strength 0.54
  13. Yan Zhao · 6 shared papers, 2018–2022 · strength 0.50
  14. Li Xu · 3 shared papers, 2019–2021 · strength 0.32
  15. Yuhui Liu · 3 shared papers, 2019–2022 · strength 0.32
  16. Min Zhou · 4 shared papers, 2018–2019 · strength 0.31
  17. Xu Li · 3 shared papers, 2018–2022 · strength 0.27
  18. Yu Bai · 1 shared paper, 2026 · strength 0.26
  19. Xuemin Chen · 2 shared papers, 2022–2023 · strength 0.25
  20. Jingdong Li · 2 shared papers, 2022–2023 · strength 0.25
  21. Yahui Liu · 2 shared papers, 2022–2023 · strength 0.25
  22. Jun Liu · 2 shared papers, 2022–2023 · strength 0.25
  23. Xianjun Yu · 2 shared papers, 2022–2023 · strength 0.25
  24. Renyi Qin · 2 shared papers, 2019–2022 · strength 0.21
  25. Xiaoxiang Wang · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.